Interestingly, mediation analysis in the trial suggested that 10.4% of the effects of canagliflozin on hospitalisation with heart failure were reflected in the lowering of NT-proBNP, suggesting that NT-proBNP is one of the mechanistic links between SGLT2i and its cardioprotective effects. The gene discussed is NPPB; the disease is heart failure.